Roivant reports Phase 2b lupus failure for an FcRn drug
4 Articles
4 Articles
Immunovant, a global partner of Hanol BioPharma, a subsidiary of Daewoong Pharmaceutical Group, decided on the 23rd (local time) to discontinue the development of a treatment for cutaneous erythema associated with lupus. On that day, Immunovant stated, "We have decided to discontinue the development of a treatment for the cutaneous erythema indication after comprehensively considering the competitive market situation." According to clinical resu…
Immunovant, a global partner of Hanol BioPharma, will stop developing lupus erythematosus (CLE) indications as candidates for autoimmune diseases. This decision is due to a failure to secure statistical significance in clinical trials. On the 23rd (local time), Immunovant announced the clinical results of proof of concept (PoC) for lupus erythematosus erythematosus (IMVT-1402)”, a treatment for autoimmune diseases. In this clinical trial, which …
Hanol Biopharma's next-generation autoimmune disease treatment 'Imerofrubat (IMVT-1402)' failed to meet the primary endpoint in a clinical trial for cutaneous lupus erythematosus (CLE).
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
